Frankfurt, Germany
Innoplexus - a Partex Company is a pioneering force in the intersection of AI technology and life sciences, aimed at transforming drug discovery and development. Founded in 2011, the company has established itself as an expert with a compelling slogan—"The expert in AI technology for drug discovery and development."
The German-headquartered firm, with additional offices in Pune, Iselin, and San Francisco, leverages cutting-edge technologies such as Artificial Intelligence, Machine Learning, and Blockchain to create a significant impact. With a substantial portfolio of over 190 US/EU patents, Innoplexus revolutionizes the speed and cost-effectiveness of drug development by offering solutions for data aggregation, clinical trial optimization, and regulatory compliance.
The company's last known funding round was a Series C investment on 01 April 2019, indicating a mature stage in its growth trajectory. Innoplexus's commitment to fostering innovation and collaboration makes it a strategic partner for big pharmaceutical companies and CROs, enabling them to bring effective treatments to market more efficiently.
